Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bumetanide

FDA-approved product (tablet, oral), marketed as Bumetanide, Bumex, Enbumyst.

Registered studies
49
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Bumetanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Kidney disease
  • Nephrotic syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bumetanide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bumetanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bumetanide vs. Furosemide in Cirrhosis

    NCT06941415 · start 2026-06-03

    Registered record
    Registry ID
    NCT06941415
    Conditions
    Cirrhosis
    Interventions
    Bumetanide; Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-06-03
    Completion
    2029-03-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    InterventionBumetanide; Furosemide
    PhasePhase 3
    Registry statusRecruiting

  • VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure

    NCT07375212 · start 2026-01-21

    Registered record
    Registry ID
    NCT07375212
    Conditions
    Heart Failure Congestive
    Interventions
    Bumetanide, intranasal 4mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2026-01-21
    Completion
    2026-01-21
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure Congestive
    InterventionBumetanide, intranasal 4mg
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models

    NCT07005414 · start 2025-06-04

    Registered record
    Registry ID
    NCT07005414
    Conditions
    Autism Spectrum Disorder
    Interventions
    Bumetanide; Treatment as usual (TAU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-06-04
    Completion
    2026-04-22
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder
    InterventionBumetanide; Treatment as usual (TAU)
    PhasePhase 2
    Registry statusCompleted

  • Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

    NCT06995144 · start 2025-05-28

    Registered record
    Registry ID
    NCT06995144
    Conditions
    Heart Failure; Edema; Pulmonary Congestion; Fluid Overload
    Interventions
    Extended Release Torsemide Tablets; Immedate Release Torsemide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-05-28
    Completion
    2025-12-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Edema; Pulmonary Congestion; Fluid Overload
    InterventionExtended Release Torsemide Tablets; Immedate Release Torsemide Tablets
    PhasePhase 4
    Registry statusCompleted

  • Diuretic Testing in Chronic Kidney Disease

    NCT06841692 · start 2025-04-01

    Registered record
    Registry ID
    NCT06841692
    Conditions
    Kidney Disease, Chronic
    Interventions
    Diuretic Testing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-01
    Completion
    2029-10-31
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Disease, Chronic
    InterventionDiuretic Testing
    PhaseNot applicable
    Registry statusRecruiting

  • Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

    NCT06209359 · start 2024-07-24

    Registered record
    Registry ID
    NCT06209359
    Conditions
    Heart Failure; Diuretic Resistance
    Interventions
    Ammonium Chloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-07-24
    Completion
    2029-03-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Diuretic Resistance
    InterventionAmmonium Chloride; Placebo
    PhasePhase 1
    Registry statusRecruiting

  • Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

    NCT06414759 · start 2024-07-01

    Registered record
    Registry ID
    NCT06414759
    Conditions
    Acute Decompensated Heart Failure; Volume Overload; Edema
    Interventions
    Acetazolamide; Metolazone; IV Loop Diuretics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2025-03-30
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure; Volume Overload; Edema
    InterventionAcetazolamide; Metolazone; IV Loop Diuretics
    PhasePhase 4
    Registry statusUnknown

  • EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)

    NCT06362668 · start 2024-05-17

    Registered record
    Registry ID
    NCT06362668
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    Reprieve Decongestion Management System; Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-05-17
    Completion
    2024-10-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    InterventionReprieve Decongestion Management System; Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Ultra High Dose Diuretics to Treat Heart Failure

    NCT06036914 · start 2023-11-27

    Registered record
    Registry ID
    NCT06036914
    Conditions
    Heart Failure; With Decompensation
    Interventions
    Bumetanide; Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-11-27
    Completion
    2024-10-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; With Decompensation
    InterventionBumetanide; Furosemide
    PhasePhase 2
    Registry statusCompleted

  • Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

    NCT05753059 · start 2023-08-10

    Registered record
    Registry ID
    NCT05753059
    Conditions
    Heart Failure
    Interventions
    Placebo; Amiloride; Bendroflumethiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-08-10
    Completion
    2028-06-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionPlacebo; Amiloride; Bendroflumethiazide
    PhasePhase 1
    Registry statusRecruiting

  • Bumetanide in Patients With Alzheimer's Disease

    NCT06052163 · start 2023-04-10

    Registered record
    Registry ID
    NCT06052163
    Conditions
    Alzheimer Disease
    Interventions
    Bumetanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-10
    Completion
    2026-12-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionBumetanide; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

    NCT05580510 · start 2023-02-06

    Registered record
    Registry ID
    NCT05580510
    Conditions
    Congenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection Fraction
    Interventions
    Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID; Empagliflozin 10 MG OD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-02-06
    Completion
    2024-03-29
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection Fraction
    InterventionSacubitril 49 MG / Valsartan 51 MG [Entresto] BID; Empagliflozin 10 MG OD
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Diuretics and Volume Overload in Early CKD

    NCT05171686 · start 2023-02-01

    Registered record
    Registry ID
    NCT05171686
    Conditions
    Chronic Kidney Disease; Hypertension
    Interventions
    Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-01
    Completion
    2025-10-02
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Hypertension
    InterventionDiuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome

    NCT06465823 · start 2023-01-11

    Registered record
    Registry ID
    NCT06465823
    Conditions
    Down Syndrome
    Interventions
    Bumetanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-01-11
    Completion
    2026-09-30
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDown Syndrome
    InterventionBumetanide; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

    NCT05503511 · start 2022-10-20

    Registered record
    Registry ID
    NCT05503511
    Conditions
    Epilepsy; Alzheimer Disease; Epilepsy Intractable
    Interventions
    NPT 2042 (bumetanide analog) or Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-20
    Completion
    2023-03-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy; Alzheimer Disease; Epilepsy Intractable
    InterventionNPT 2042 (bumetanide analog) or Matching Placebo
    PhasePhase 1
    Registry statusCompleted